ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma
Photo by Robina Weermeijer on Unsplash

ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma

According to a news release, researchers from biopharmaceutical company HUTCHMED and pharmaceutical company AstraZeneca launched, at the onset of November 2021, the Phase 3 SAMETA clinical trial. During the trial,…

Continue Reading ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma
Computer Simulation Shows Surgery is Overprescribed for Kidney Cancer Patients
source: pixabay.com

Computer Simulation Shows Surgery is Overprescribed for Kidney Cancer Patients

The most common treatment for someone who is discovered to have early stage kidney cancer is surgery. The patient's tumors and a part of their kidneys are removed through a…

Continue Reading Computer Simulation Shows Surgery is Overprescribed for Kidney Cancer Patients